Immunotherapy Advances for Colorectal Carcinoma in 2018 - prIME Oncology
Clinical Spotlight
Clinical Spotlight

Immunotherapy Advances for Colorectal Carcinoma in 2018

Newly Released Data From the Gastrointestinal Cancers Symposium in San Francisco

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Get expert insight on the most important data on immunotherapy in colorectal cancer presented at the 2018 Gastrointestinal Cancers Symposium.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Newsflash

Newsflash

Release Date

Release Date

Jan 30, 2018

Expiration Date

Jan 23, 2019

Abstract #553: Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142

Abstract #554: Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142

Abstract #560: A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC)

  • Johanna Bendell, MDSarah Cannon Research Institute
    Nashville, Tennessee, United States
  • Axel Grothey, MDMayo Clinic
    Rochester, Minnesota, United States
  • Ian Chau, MDRoyal Marsden Hospital
    London, United Kingdom

After successful completion of this educational activity, participants should be able to:

  • Select patients with mCRC that benefit from immune checkpoint single-agent therapy
  • Describe the rationale for immunotherapy in colorectal cancer, both as a single agent and in combination with targeted therapies
  • Assess recent clinical trial data from studies involving immune checkpoint inhibitor-based treatment strategies in colorectal cancer

This educational activity is supported by a grant from F. Hoffmann-La Roche Ltd.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This educational activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.